Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Operating Expenses: 2021-2023

Historic Operating Expenses for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to $45.5 million.

  • Cullinan Therapeutics' Operating Expenses rose 39.49% to $45.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $190.6 million, marking a year-over-year increase of 44.28%. This contributed to the annual value of $196.9 million for FY2024, which is 3.29% up from last year.
  • Per Cullinan Therapeutics' latest filing, its Operating Expenses stood at $45.5 million for Q4 2023, which was up 1.52% from $44.8 million recorded in Q3 2023.
  • Cullinan Therapeutics' 5-year Operating Expenses high stood at $62.8 million for Q1 2023, and its period low was $16.6 million during Q2 2021.
  • For the 3-year period, Cullinan Therapeutics' Operating Expenses averaged around $34.1 million, with its median value being $33.5 million (2021).
  • Examining YoY changes over the last 5 years, Cullinan Therapeutics' Operating Expenses showed a top increase of 123.48% in 2022 and a maximum decrease of 5.06% in 2022.
  • Cullinan Therapeutics' Operating Expenses (Quarterly) stood at $34.3 million in 2021, then fell by 5.06% to $32.6 million in 2022, then spiked by 39.49% to $45.5 million in 2023.
  • Its Operating Expenses stands at $45.5 million for Q4 2023, versus $44.8 million for Q3 2023 and $37.6 million for Q2 2023.